Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
Lumira Ventures is pleased that LQT Therapeutics has announced the closing of US$19M Series A financing to advance lead compound through Phase 1
August 10, 2021
LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19... Learn More
July 28, 2021
- Angelini Pharma will invest US$35 million and be the sole investor in this innovative fund - ALBF will invest in early-stage companies developing pharmaceuticals to treat central nervous system... Learn More
Lumira Ventures Closes on US$255 Million of New Capital to Build Transformative Healthcare Companies
July 26, 2021
Oversubscribed Lumira Ventures IV to continue successful focus backing biotechnology and medtech companies in Canada and U.S. Companion strategic fund formed in partnership with international... Learn More
July 19, 2021
With the establishment of Lumira Ventures Fund IV, the largest life sciences focused venture fund ever raised in Canada, we launched our Lumira Ventures Venture Innovation Program (Lumira... Learn More
Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
"Lumira's philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael's ability to accelerate the pace."
Dr. Arthur Slutsky | Vice-President
Vice-President of Research at St. Michael's Hospital
"Lumira's model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation."
Barbara Grantham | President & Ceo
VGH & UBC Hospital Foundation
“This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”
Paul Alofs | President & Ceo
Princess Margaret Cancer Foundation
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
141 Adelaide Street
Canada, M5H 3L5
3, Place Ville Marie
Bureau 12350, Niveau L
Canada, H3B 0E7
1021 West Hastings Street,
Canada, V6E 0C3
303 Wyman Street